Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics 2016 to 2024

$3,995.00

Asset Purchase Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2024

Publication date
September 2024
Number of pages
500+
Product type
Research report
Available formats
PDF document
Report edition
5 - fully revised and updated
SKU
CP2054

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty asset purchase deals.

The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

The report focuses on four primary types of asset available for purchase:

  • Business assets
  • Product assets
  • Royalty assets
  • Technology assets

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of asset purchase deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of asset purchase deals.

Chapter 4 provides a review of the leading asset purchase deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active asset purchase dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.  

Chapter 6 provides a comprehensive and detailed review of asset purchase deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.

The deal directory includes a comprehensive listing of all asset purchase deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.

 

Key benefits

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse asset purchase deals
  • Benchmark analysis – identify market value of transactions
  • Financials - headline, upfront, milestone, royalty rates
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

 

Report scope

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics includes:

  • Trends in asset purchase dealmaking in the biopharma, medical device and diagnostics industries
  • Overview of asset purchase deal structure
  • Directory of asset purchase deal records covering pharmaceuticals, biotechnology, medical devices and diagnostics
  • The leading asset purchase deals by value
  • Most active asset purchase dealmakers
  • The leading asset purchase partnering resources

 

In Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

 

Each deal title links via hyperlink to an online version of the actual deal record, providing easy access to each contract document where available.

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides comprehensive access to available records for asset purchase deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the rights granted or optioned?
  • What rights are granted by the agreement?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are intellectual property rights handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Asset Purchase Deals in Pharmaceuticals, Biotechnology, Medical Devices and Diagnostics provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse asset purchase deals
  • Benchmark analysis – identify market value of transactions
  • Financials - headline, upfront, milestone, royalty rates
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in asset purchase dealmaking

2.1. Introduction

2.2. Types of assets purchased

2.3. Trends in asset purchase deals since 2016

2.3.1. Asset purchase dealmaking by year, 2016-2024

2.3.2. Asset purchase dealmaking by phase of development, 2016-2024

2.3.3. Asset purchase dealmaking by industry sector, 2016-2024

2.3.4. Asset purchase dealmaking by therapy area, 2016-2024

2.3.5. Asset purchase dealmaking by technology type, 2016-2024

2.3.6. Asset purchase dealmaking by most active company, 2016-2024

2.4. Reasons for entering into asset purchase partnering deals

2.4.1. Business assets

2.4.2. Product assets

2.4.3. Royalty assets

2.4.4. Technology assets

2.5. The future of asset purchase deals

 

Chapter 3 – Overview of asset purchase deal structure

3.1. Introduction

3.2. Asset purchase agreement structure

 

Chapter 4 – Leading asset purchase deals

4.1. Introduction

4.2. Top asset purchase deals by value

 

Chapter 5 – Top 25 most active asset purchase dealmakers

5.1. Introduction

5.2. Top 25 most active asset purchase dealmakers

 

Chapter 6 – Asset purchase deals including contracts directory

6.1. Introduction

6.2. Asset purchase deals with contracts 2016-2024

 

Deal directory

Deal directory – Asset purchase dealmaking by companies A-Z

Deal directory – Asset purchase dealmaking by therapy area

Deal directory – Asset purchase dealmaking by technology type

 

About Biopharma Research Ltd

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

TABLE OF FIGURES

Figure 1: Definition of assets purchased

Figure 2: Trends in asset purchase deal announcements, 2016-2024

Figure 3: Asset purchase deals signed at each phase of development, 2016-2024

Figure 4: Asset purchase deals by industry sector, 2016-2024

Figure 5: Asset purchase deals by therapy area, 2016-2024

Figure 6: Asset purchase deals by technology type, 2016-2024

Figure 7: Top 25 most active asset purchase dealmakers, 2016-2024

Figure 8: Top asset purchase deals by value, 2016-2024

Figure 9: Most active asset purchase dealmakers, 2016-2024

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $7,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Biopharma Research Ltd based in York, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3CL Sciences, 3M, 3SBio, 4D Molecular Therapeutics, 4SC, 7D Surgical, 9 Meters Biopharma, 30 Technology, A&E Medical, Aardvark Therapeutics, Abbott Laboratories, Abbvie, Abcam, AbCellera Biologics, ABEC, Acacia Research, Academy Medical, Acare Medical Science, Accelus, Accord, Accuray, Acelity, Achaogen, AC Immune, Acino Pharma, Aclaris Therapeutics, Acorda Therapeutics, Acrotech Biopharma, Actavis (acquired by Watson), Actelion, ACT Genomics, Acutus Medical, Adalvo, Adamis Pharmaceuticals, Adaptas Solutions, AdaptHealth, Additive Orthopaedics, Adello Biologics, Adhera Therapeutics, Adial Pharmaceuticals, ADMA Biologics, adMare BioInnovations, Admedus, Adovate, Advanced Accelerator Applications, Advanced BioMatrix, Advanced Facialdontics, Advanced Neural Dynamics, Advanced Tear Diagnostics, Advanomics, AdvanSource Biomaterials, ADvantage Therapeutics, Advanz Pharma, Advent International, Advicenne, Aerie Pharmaceuticals, Aethon Therapeutics, Aevitas Therapeutics, AFFiRiS, AGC Asahi Glass, AGC Biologics, AgeX Therapeutics, Agios Pharmaceuticals, Agrium, AiPing Pharmaceutical, Akida, Akkadeas Pharma, Akorn, Akoya Biosciences, Akrimax Pharmaceutical, Alaya.bio, Albumedix, Alcon Laboratories, Aleafia Health, Aleph Farms, Alere, Alexion Pharmaceuticals, Alexza Pharmaceuticals, Alfasigma, Alfred E. Mann Institute for Biomedical Engineering, Algernon Pharmaceuticals, AliveGen, ALK-Abello, Allegheny General Hospital, Allegis Pharmaceuticals, Allergan, Allergan Aesthetics, AllerQuest, Alliance Pharma, Ally Biotech, Almirall, Alphagen Laboratories, Alpine Immune Sciences, Altaris Capital Partners, Altavant Sciences, Altermune Technologies, Alvine Pharmaceuticals, Alvogen, Amarantus BioSciences, Amerigen Pharmaceuticals, AmerisourceBergen, Amgen, Amneal Pharmaceuticals, Ampersand Capital Partners, Amphastar Pharmaceuticals, AmplifyBio, AmpliPhi Biosciences, Amplyx Pharmaceuticals, Ampronix, AMP Therapeutics, Amring Pharmaceuticals, Amygdala Neurosciences, Amylyx Pharmaceuticals, Amyris, Angelini Pharma, Angiodynamics, ANI Pharmaceuticals, Antares Pharma, Antylia Scientific, Apeiron Biologics, Apollo Endosurgery, ApoPharma, Apotex, Applied Biology, Applied StemCell, Applied UV, Aptevo Therapeutics, APT Therapeutics, Aradigm, Aralez Pharmaceuticals, Araris Biotech, aratinga.bio SAS Group, Arcadia Consumer Healthcare, argenx, Argon Medical Devices, ArisGlobal, Arivis, Arjo, Arkuda Therapeutics, Armetheon, Arranta Bio, Arrevus, ARS Pharmaceuticals, Arteriocyte Medical Systems, Arthrosurface, Artisan Bio, Artizan Biosciences, Arvinas, Arysta LifeScience, Ascend Advanced Therapies, Asklepios Biopharmaceutical, Aspargo Laboratories, Aspen Holding, Aspen Pharmacare Canada, Aspen Surgical Products, Assembly Biosciences, Assertio Therapeutics, Assisi Animal Health, Astellas Pharma, Astero Bio, AstraZeneca, Astrea Pharma, Atara Biotherapeutics, ATEC Spine, Athenex, Atlab Pharma, ATL Technology, Atnahs Pharma, ATP, Atreca, Audax Private Equity, Augmedics, AUG Therapeutics, AuraGen Aesthetics, Auris Medical, Aurobindo Pharma, Aurora Cannabis, AuxoCell Laboratories, Avadel Pharmaceuticals, Avalo Therapeutics, Avantor, Avara Pharmaceutical Services, Avenue Therapeutics, Avicanna, Avid Bioservices, Avrobio, AXIM Biotechnologies, Axonics, AxoSim, Ayala Pharmaceuticals, Aytu BioPharma, Azaya Therapeutics, Banco de Sangre de Servicios Mutuos, Baptist Health Care, Baring Private Equity Asia, BarioSurg, Basilea Pharmaceutica, Bausch & Lomb, Bausch Health Companies, Bavarian Nordic, Baxalta, Baxter International, Bayer, Bayer Animal Health, Bayer Healthcare, BBI Solutions, B Braun, Beacon Therapeutics, Beartooth Therapeutics, Becton Dickinson, Beiersdorf, BeiGene, Beijing Genomics Institute (BGI), Bellicum Pharmaceuticals, Bellin Health, Bellus Health, Benuvia Therapeutics, Benvenue Medical, Berkeley Lights, BetterLife Pharma, BGI, Bial, Bigfoot Biomedical, Bio-Rad Laboratories, Bioanalytical Laboratory Services, BioClinica, Biocon, BioCorRx, BioDelivery Sciences, Biodelta Nutraceuticals, Biodesix, Biogen, Bio Innovation Group, BioMedion, Biomerics, BioMotiv, Bionik Laboratories, BioNTech, BioNxt Solutions, BioPharma Services, BiopharmX, Biora Therapeutics, BioReference Laboratories, BioSig Technologies, BioStem Technologies, Biostem US, BioTelemetry, Biotest Pharmaceuticals, BioVaxys, Bioventus, BioVie, Blood and Plasma Research, Bluebird Bio, Bluelink Pharmaceuticals, Blue Water Biotech, Blue Water Vaccines, Blumentech, BMG Pharmaceuticals, Boehringer Ingelheim, Boehringer Ingelheim Vetmedica, Bolt Biotherapeutics, Bone Therapeutics, Bora Pharmaceuticals, Boston Scientific, Boston Topicals, Botanix Pharmaceuticals, Bovie Medical, BoxView, Brainsway, Breckenbridge Pharmaceutical, Brickell Biotech, BridgeBio Pharma, Bridge to Life, Bridgewest Group, Briggs Healthcare, Brii Biosciences, Bristol-Myers Squibb, BroadOak Capital Partners, Bruker, BUCHI Labortechnik, Burgerhospital, BVI Medical, BWX Technologies, C2Dx, C3J Therapeutics, C4X Discovery, Calibre Scientific, California Institute for Biomedical Research, Cambus Medical, CanAm Bioresearch, Candela, Candel Therapeutics, Cannabis Manufacturer’s Guild, Cannara Biotech, Canon BioMedical, Cantel Medical, Caprion Proteomics, CaptoGlove, Cardinal Health, CardioFocus, Cardiome Pharma, CardioSert, Cardiovascular Systems, Carestream Health, Caret Pharma, Carterra, CASI Pharmaceuticals, CAS Medical Systems, Casper Pharma, Castle Biosciences, Catalent, Catalyst Biosciences, Catheter Research, CBL Group, Cedars-Sinai Medical Center, Celator, Celdara Medical, Celgene, Celgene Cellular Therapeutics, Cell Biosciences, Celling Biosciences, Cellistic, Cellmic, CellReady, Celltrion, Celonic, Celsee, Celularity, Celyad, CEM, CEN Biotech, Centauri Therapeutics, Centene, Centinel Spine, Centre for Probe Development and Commercialization, Centrexion, Centurion Medical Products, Century Medical, Cequr, Cerebain Biotech, Cerecor, Certara, Cerulean Pharma, Cerus, Chembio Diagnostics, Cheplapharm Arzneimittel, Chiesi Farmaceutici, China Medical System, China Pharma Holdings, ChoiceSpine, Chroma Therapeutics, Chronos Therapeutics, Cilag AG, Cinven, Cipher Pharmaceuticals, Cipla, Circadian Wellness, Cirrus Dx, Cirrus Pharmaceuticals, CJ CheilJedang, Clarus Therapeutics, Clayton Dubilier & Rice, Clinique Les Trois Soleils, Clovis Oncology, Co-Diagnostics, Co.Don, Codan Triplus, Codexis, Codiak BioSciences, Coeptis Pharmaceuticals, Coherus Biosciences, College Park Industries, Collegium Pharmaceuticals, Colorcon, Concert Pharmaceuticals, Concord Biosciences, Confluent Medical Technologies, ConforMIS, Context Therapeutics, Contura, ConvaTec, Conventus Orthopaedics, Cook Medical, Cooper-Vemedia, Cooper Companies, Cooper Surgical, Corden Pharma, Cordis, Corin, CorMatrix Cardiovascular, Coronado Biosciences, Corza Health, Corza Medical, Cosette Pharmaceuticals, Covance, Covestro, Covis Pharmaceutical, Covistat, Cranford Pharmaceuticals, C R Bard, CR Kennedy & Company, CROMA Pharma, Crosswalk Therapeutics, Crown Laboratories, Cryolife, CSPC Pharmaceutical Group, CTD Holdings, CTI BioPharma, Cullinan Oncology, Cumberland Emerging Technologies, Cumberland Pharmaceuticals, Curaleaf, CURE Pharmaceutical, Curi Bio, Curon Biopharmaceutical, Custopharm, CVC Capital Partners, Cybin, Cyclerion Therapeutics, CYduct Diagnostics, Cynata Therapeutics, Cypralis, Cyprium Therapeutics, Cytek Biosciences, CytoMed Therapeutics, Cytonet, Cytori Therapeutics, Cyxone, Daiichi Sankyo, Daniel Alain Life Science, Dartmouth College, Dascena, DAS Therapeutics, Daylight Medical, DeciBio Consulting, Delpharm, Delta, Denovo Biopharma, Dentsply International, Department of Veterans Affairs, DePuy, DermaPort, Dermira, DermOQ, Desert Medical Campus, Desma HC, DeuteRx, DiamiR, DiaSorin, DifGen Pharmaceuticals, Dilon Diagnostics, Distal Access, Diversey Care, DJO Surgical, Dong-A Pharmaceutical, DOSE Medical, Dr. Reddy's Laboratories, DS Healthcare, DSM, DSM Nutritional Products, DT MedTech, Dualogics, Ducere Pharma, Dune Medical Devices, DuPont, Durect, Dutch Emotional Brain, EaglePicher Technologies, Eckert & Ziegler, Edan Diagnostics, Eddingpharm, Eden Biologics, EdiGene, Edison Nation, Editas Medicine, Edogawa Hospital, Edwards Lifesciences, Egalet, Ehave, Eiger BioPharmaceuticals, E Ink, Elanco, Elanix Biotechnologies, Electrical Geodesics, Elekta, Elektron Eye Technology, Elencee, Eleven Biotherapeutics, Eli Lilly, ELT Sight, Eluminex Biosciences, Emboline, Embolitech, Emerald Health Therapeutics, Emergent BioSolutions, Emmes, Empyrean Medical Systems, EnBiotix, Encore Medical, EndoCeutics, Endogastric Solutions, Endonovo Therapeutics, Endo Ventures, Enko, EnteroMedics, Entheon Biomedical, Envigo, Environmental Tectonics Corporation, Envisia Therapeutics, Envista, EnWave, Enzyvant Science, EpiBiome, Epigenomics, EPI Health, Eppendorf, Equillium, Erytech Pharma, Escape Therapeutics, Espada Dermatology, Essential Pharma, Essential Pharmaceuticals, Eterna Therapeutics, Ethicon Endo-Surgery, Ethismos Research, Eton Pharmaceuticals, Eurobio Scientific, EUSA Pharma, Euthymics Bioscience, Evonik Industries, Evotec, Evox Therapeutics, Exacis Biotherapeutics, Exactech, Exelixis, Expedeon, Exuma Biotech, Eyevance, Ferring Pharmaceuticals, Finch Therapeutics, Firsthand Technology, Flagship Biosciences, Flamma, Flexion Therapeutics, Flexpoint Sensor Systems, FMC, Focus Laboratories, FORMA Therapeutics, Fortive, Fosun Pharmaceutical, Fougera Pharmaceuticals, Foundation Consumer Healthcare, Fox Chase Chemical Diversity Center, Frankfurt University Hospital, Freedom Innovations, Fresenius Kabi Pharmaceuticals, Fresenius Medical Care, Fresh Tracks Therapeutics, Freudenberg Medical, Freya Pharma Solutions, Fujifilm, Fujifilm Diosynth Biotechnologies, Fusion Pharmaceuticals, G&W Laboratories, Galapagos, Galderma, Galen, Galgo Medical, Galvanize Therapeutics, GamaMabs Pharma, Gamma Medica, Gardia Medical, GC Pharma, GE Healthcare, Genentech, GenePOC, GeneQuine Biotherapeutics, Genesis Biotechnology Group, Genesis MedTech, Genetrix, GeneWorks, Genezen, Genomic Health, Genovac, George Clinical, Germfree, Gesynta Pharma, Gilead Sciences, Ginkgo BioWorks, GI Reviewers, Givaudan, Glaukos, GL Capital Group, Glenmark Pharmaceuticals, Global Medical Solutions, Globus Medical, Glycotope Biotechnology, Gowan Crop Protection, GPI Group, GrandOmics Biosciences, Gravitas Therapeutics, Great Belief International, Greenteaspoon, GRI Bio, Grifols, Grunenthal, GSK, GT Biopharma, GT Medical Technologies, Guangdong Lewwin Pharmaceutical Research Institute, Guerbet, GVS, Gyrus Capital, H-CYTE, H2-Pharma, Hackensack University Medical Center, Haemonetics, Halo Labs, Halyard Health, Harrow Health, Havn Life Sciences, HCA Healthcare, Healeon Medical, Healion Bio, Healiva, Health Outcomes Sciences, HeartBeam, HeavenlyRx, heliosDX, Hellman & Friedman, Henry Ford Health System, Henry Schein, Hera Biotech, Heritage Group, Heritage Pharmaceuticals, High Ridge Brands, Hikma Pharmaceuticals, Hill-Rom, Hillstream BioPharma, HLS Therapeutics, HMNRTH, Hoffmann La Roche, Holmdel Pharmaceuticals, Hologic, Horizon Discovery, Howard Foundation, Howmedica Osteonics, HOYA Vision Care, HS Pharmaceuticals, HTL Biotechnology, Hubro Therapeutics, Humanetics, Humanitas University, Human Longevity, Huntsman, Hutchinson Technology, Hutchison China MediTech, Hypera Pharma, I-mab, i2 Pharmaceuticals, iAnthus Capital, IASO Biotherapeutics, IBA, IBA Molecular Imaging, iCAD, Icagen, ICU Medical, IDEAYA Biosciences, Idorsia, IEH Laboratories & Consulting Group, IFM Therapeutics, Igenica, Iktos, IlmixGroup, Imagin Medical, Immuneed, ImmuneHealth, Immune Therapeutics, ImmunGene, Immunic, ImmunityBio, ImmunoCellular Therapeutics, ImmunogenX, Immunome, Impax Laboratories, Imugene, IMV, Inceptor Bio, Incyte, Indivior, INEX Innovate, Infab, InfusAID, InfuSystem Holdings, Initiator Pharma, Innospec, INNOVAMEDICA, Innovation Skane, Innovent Biologics, Innovus Pharmaceuticals, iNova Pharmaceuticals, Inozyme Pharma, Inserm, In Silico Biosciences, Inspirata, Instem, Institut du Cancer Courlancy, Insulet, Intas Pharmaceuticals, Intavis Bioanalytical Instruments, Integra LifeSciences, Integrated DNA Technologies, Integrated Proteomics Applications, Integrative Medicine, IntegriChain, Intermountain Precision Genomics, International Biomedical, International Isotopes, International Process Plants, International Vitamin, Interpace BioPharma, Interventional Spine, IntraFuse, Invekra, Invitae, Ionic Brands, Ipsen, iQ Group, IQVIA, Iridex, Iroko Pharmaceuticals, Irras, IRX Therapeutics, Isologic Innovative Radiopharmaceuticals, IsoPlexis, IsoRay, Isto Technology, Itamar Medical, Iveric Bio, Ixaka, J. Morita, Janssen Biotech, Janssen Diagnostics, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Sciences, Japan Tobacco, Jazz Pharmaceuticals, Jefferson Healthcare, Johnson & Johnson, John Wiley and Sons, Jolt Health, Journey Medical, JT Pharmaceuticals, Juvise Pharmaceuticals, Kala Pharmaceuticals, Kamada, Kancera, Kane Biotech, karmadata, Karo Pharma, Karyopharm Therapeutics, Kashiv BioSciences, KBP BioSciences, KD Pharma, Kedrion, KemPharm, Kemwell BioPharma, Kimberly-Clark, Kincell Bio, Kindstar Globalgene Technology, Kiniksa Pharmaceuticals, Kinnate Biopharma, Kite Pharma, Klogenix, KNOW Bio, Kohlberg Kravis Roberts (KKR), Kolltan Pharmaceuticals, Korsch, Kramer Laboratories, Kronos Bio, Kuros Biosciences, Kyocera, L'Oreal, L3Harris Technologies, Laboratoires DELBERT, Laboratoire Serb, Laboratoires Thea, Laboratorio Medinfar, Laboratorios Rubio, Laboratory Corporation of America, Labworks, La Jolla Institute for Allergy & Immunology, Landos Biopharma, Lannett, Lantheus Holding, Lanzhou Ion Therapy, Laurel Venture Capital, Lautus Pharmaceuticals, LeMaitre Vascular, LensAR, LEO Pharma, Les Laboratoires Servier, Lexicon Pharmaceuticals, LGC, LI-COR Biosciences, Lifecode, Lifecycle Biotechnologies, Lifenet, Ligand Pharmaceuticals, Lighthouse Pharmaceuticals, Liminal BioSciences, Lincotek Medical, LindaCare, Lineage Cell Therapeutics, LineaRx, Link Fund Solutions, Link Immunotherapeutics, LivaNova, LIVMOR, Lobe Sciences, Lobesity Pharma, Locus Biosciences, Longitude Capital, Lonza, Lorem Vascular, LOTTE, Lotus Biotechnology Development, Loxo Oncology, LTL Pharma, LTS Lohmann Therapie-Systeme, Lucy Scientific Discovery, Luitpold Pharmaceuticals, Lumenis, LumenR, Luminera, Luminex, LumiraDx, LumiThera, Lumos Pharma, Luye Pharma Group, MAB Discovery, MabVax Therapeutics, Macrogen, Macrogenics, MacuHealth, MacuLogix, Magstim, Mainz Biomed, Malin, Mallinckrodt Pharmaceuticals, Mandos, MannKind Biopharmaceuticals, Maravai LifeSciences, Marina Biotech, Marin Community Foundation, Marinus Pharmaceuticals, Marizyme, Marker Therapeutics, Masimo, Matrivax, Matrox, Mayne Pharma, Mayo Clinic, MC10, McKesson, MD Anderson Cancer Center, MDNA Life Sciences, MDxHealth, MEDCIS Pathlabs, Medeon Biodesign, MedGenome, Medical Developments International, Medical University of Vienna, Medican Enterprises, Medicom, Medicure, Medidata Solutions, MediGene, Medigus, Medimetrics, MediPines, Medivir, Medline Industries, Mednax, MedPlast, Medtronic, Megadalton Solutions, Meilleur Technologies, Meitheal Pharmaceuticals, Melinta Therapeutics, Menarini, Menarini Asia-Pacific, Mentice, Merck and Co, Merck Animal Health, Merck KGaA, Merck Sharpe & Dohme, Meridian Bioscience, Merit Medical Systems, Merrimack Pharmaceuticals, Merus Labs International, Merz Therapeutics, METabolic EXplorer, Metabolix, Metrion Biosciences, Microba Life Sciences, Microbot Medical, Microlin Bio, MicroPort Scientific, Microsoft, MiGenTra, Mikart, MilliporeSigma, Minapharm, Mind Medicine, Minerva Surgical, Miravo Healthcare, Mirum Pharmaceuticals, Mitralign, Mitsubishi Chemical, MLase, MMT Technologies, Moberg Pharma, Modernizing Medicine, Modern Meadow, Modulus Therapeutics, MolecuLight, Molnlycke Health Care, Molplex Pharmaceuticals, Molteni Farmaceutici, Momentis Surgical, MorphoSys, Mountain Valley MD, Mount Sinai Health System, MSC, MTD, Mucokinetica, Mustang Bio, Myconic Capital, Mylan Laboratories, Mylan Pharmaceuticals, Myovant Sciences, Myriad Genetics, Naari Pharma, Nabriva Therapeutics, Nanion, Nanjing King-friend Biochemical Pharmaceutical, NanoProteagen, Nanotherapeutics, NantHealth, Natera, National Cancer Center, National Resilience, Natus Medical, Navidea Biopharmaceuticals, NEC OncoImmunity, NEMO Health, Neogen, Neograft Technologies, Neosurgical, NeoSync, Neovasc, Nephron Pharmaceuticals, Neptune Wellness Solutions, Nestle, Nestle Health Science, NeuBase Therapeutics, Neuraxpharm, NeurMedix, Neuro-Kinesis Corporation, NeuroBo Pharmaceuticals, NeuroOne, Neuropathix, NeuroSearch, Nevakar, New Day Diagnostics, Newport Research, New York Blood Center, Nexelis, Nexeon MedSystems, Nextmune, Nido Surgical, Nika Pharmaceuticals, NImmune Biopharma, Nines, Nitiloop, NLC Pharma, NLT Spine, NOHO, Noramco, Nora Pharma, Nordion, Norgine, North American Partners in Anesthesia, North American Science Associates, Northwestern Memorial Hospital, Nostrum Pharmaceuticals, NovAccess Global, Novan, Novan Therapeutics, Novartis, Novarum, Novasep, Noventia Pharma, NovImmune, Novogene, Novolytics, Novo Nordisk, NOW Diagnostics, Nuclera, Nufarm, Nuvisan Pharma Services, NYU Langone Medical Center, Oakrum Pharma, OBI Pharma, ObsEva, Occlugel, Octant, Ocugen, Oculus Innovative Sciences, Odyssey Health, OhioHealth, Olon, Omeros, OmniaBio, Oncimmune, Oncodesign, Oncologie, Oncopeptides, OncoQuest, OncoVision, Onkos Surgical, Ono Pharmaceutical, OpenBiome, OpenGate Capital, Opus Genetics, Oragenics, Orchard Therapeutics, Orexigen Therapeutics, Orexo, Orgenesis, Orifarm, Orphazyme, Orsenix, Orthofix Medical, Orum Therapeutics, OSE Immunotherapeutics, OsteoCentric Technologies, Osteomed, Otifex Therapeutics, Otonomy, Otsuka America Pharmaceutical, Ottawa Hospital Research Institute, OxyPharma, Pacific Biosciences, PACT Pharma, Padagis, Palatin Technologies, Palisade Bio, PanTheryx, Paragon 28, ParaPRO, Parexel, Partner Therapeutics, Pascal Biosciences, Patagonia Pharmaceuticals, PathAI, Patient Genesis, Paulaur Corporation, PaxMedica, Peak Rock Capital, Pearsanta, PEAR Therapeutics, PentixaPharm, Performance Health, PeriGen, Periphagen Holdings, PerkinElmer, Perkins Healthcare Technologies, Pernix Therapeutics, Perrigo, Perry Baromedical, Perspective Therapeutics, PetIQ, Pfizer, Pharmaceutical Associates, Pharmacia, Pharmacolog, Pharmacyclics, PharmaEngine, PharmaLogic, Pharma Logistics, Pharmanovia, Pharmapar, Pharmaron, PharmaTher, PhaseBio Pharmaceuticals, Phenomics Health, Phoenixus, PhotoMedex, Photonamic GmbH, Piedmont Pharmaceuticals, Pierre Fabre, Pierrel, Piramal, Piramal Healthcare, Pixium Vision, PKG, Plus Therapeutics, PLx Pharma, Polypeptide Laboratory, Poolbeg Pharma, Pragma Pharmaceuticals, Praha Vaccines, Precera Bioscience, Precisa Medical Instruments, Precision Biomonitoring, Precision Eye Services, Precision Neuroscience, Premier Inc, PrepMD RMS, Presbia, Pressure BioSciences, Prestige Brands, Prestige Consumer Healthcare, Prevent Biometrics, Primavera Capital Group, Primex Pharmaceuticals, Prisma Health, ProBioGen, ProBiora Health, ProciseDx, Procter & Gamble, Profound Medical, Progenics Pharmaceuticals, Progenity, ProKidney, Proliant Health and Biologicals, ProMed Pharma LLC, Promethera Biosciences, Promius Pharma, Propel Labs, Propel Orthodontics, Prophase Labs, ProQR Therapeutics, Proteor, Proteus Digital Health, Prothelia, Prothena, Provention Bio, Psomagen, Pulse Biosciences, Pulssar Technologies, Puration, PureTech Health, Purnovate, Q2 Solutions, Qiagen, QPS, QT Vascular, Qualigen, Quest Diagnostics, Quidel, Quince Therapeutics, Quintiles IMS Holdings, Radian, Radius Health, Rafarma Pharmaceuticals, Rakuten Medical, Ra Medical Systems, RaNA Therapeutics, Randob Labs, Rasna Therapeutics, Rayner Surgical, RaySearch Laboratories, Real Brands, Realm Therapeutics, Recipharm, Reckitt Benckiser, Recordati, Rediscovery Life Sciences, RedPoint Medical3D, Redx Pharma, ReLive Biotechnologies, Remedy Pharmaceuticals, Renaissance Acquisition Holdings, Renovis, ReShape Lifesciences, ReShape Medical, Resilience, Resonetics, Retinagenix, RetroSense Therapeutics, Reverie Labs, Revive Therapeutics, Revogenex, Rexgenero, Rex Medical, Rio Grande Neurosciences, Roam Analytics, Roche, Rodo Medical, Rohner, Roivant Sciences, Rosemont Pharmaceuticals, RoundTable Healthcare Partners, RoverMed BioSciences, Roxall, Royal Philips Electronics, RTI Surgical, Rubius Therapeutics, Rumpus Therapeutics, Safegard Medical, SafeWire, Saladax Biomedical, Salarius Pharmaceuticals, Salvin Dental Specialties, Sample6, Samsung Bioepis, Samsung Biologics, Sandoz, Saniona, Sanofi, Santen Pharmaceutical, Sanuwave Health, Saol Therapeutics, Sarcomatrix Therapeutics, Saringer Life Science Technologies, Sartorius Stedim Biotech, Savant HWP, Sawai Pharmaceuticals, Scailyte, Scantox, Scapa Healthcare, Science 37, Science Corporation, Scion Solutions, Scynexis, Sea Lane Biotechnologies, Searchlight Pharma, SeaSpine, Sebacia, Sectra, SeD Biomedical, Seelos Therapeutics, Selenity Pharmaceuticals, Seneca, Sensus Healthcare, Sentynl Therapeutics, Septerna, SERB Pharmaceuticals, Serenity Bioworks, Seres Therapeutics, Seyltx, Shandong Boan Biological Technology, Shandong Xinhua Pharmaceutical, Shardna, Sharp Fluidics, Sharps Technology, Shenzhen Beimei Pharmaceuticals, Shionogi, Shire Human Genetic Therapies, Shire Laboratories, Shire Pharmaceuticals, Shoppers Drug Mart, Shoreline Biosciences, Shorla Oncology, Sibannac, Sienna Biopharmaceuticals, Sientra, Sierra Oncology, Sigma Analytical Services, Signati Medical, Signet Healthcare Partneers, Silk Road Therapeutics, Silony Medical, Simplyfeye, Simtra BioPharma Solutions, Singulex, SI Pharmaceuticals, Sirio Pharma, Sirona Medical, SIT Laboratorio Farmaceutico, SK Capital Partners, Skin Products, Sloan Pharma, SmartBreast, Smith & Nephew, Smiths Medical, Social Reality, SOCPRA Sciences Sante et Humaines, SofPulse, Sofregen Medical, Sohm, Sol-Gel, Solulink, Solvay, Sonic Healthcare, Sorrel Medical, Sorrento Therapeutics, Sorse Technology, Sosei, Southern Research Institute, Spacelabs Healthcare, Spark Therapeutics, Spartan Medical, Spear Pharmaceuticals, Spectrum Pharmaceuticals, Spinal Elements, SpineThera, Spiral Therapeutics, Sproutly, Spry Health, SQI Diagnostics, STADA Arzneimittel, Stanford Health Care, Starboard Medical, Stark Investments, Starpharma, Steeper Group, Stellar Biotechnologies, StemBioSys, StemoniX, Stericycle, Steris Corporation, St Jude Medical, Strand Life Sciences, STRATA Skin Sciences, Straumann, Strongbridge Biopharma, Stryker, SugarLeaf Labs, Sumitomo Dainippon Pharma, Sumitovant Biopharma, Summit Biolabs, SunMed, Sun Pharmaceutical, Sunshine Biopharma, Sunstar Suisse, Super-T Cell Cancer, SuperiorVAS, Supernus Pharmaceuticals, Surgalign, Surgical Specialties, SurModics, SWAT Medical AB, Swedish Orphan Biovitrum, Symmetry Surgical, Symplmed Pharmaceuticals, Synaptive Medical, Synergetics, Synergy Pharmaceuticals, SynGen, Syngene International, Synsight, Synthetic Genomics, Syros Pharmaceuticals, Systagenix Wound Management, Tabuk Pharmaceutical, Taiho, Taisho Pharmaceutical, Takeda Pharmaceutical, Talaris Therapeutics, Tamir Biotechnology, Targacept, Targovax, Taro Pharmaceuticals, Tasly Pharmaceuticals, Tec-Pharm, Tecan, Teijin Nakashima Medical, TekCyte, Teleflex, Teligent, Telix Pharmaceuticals, Terran Biosciences, TerSera Therapeutics, Terumo, Tesaro, Tesla Digital, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, The DNA Company, The Green Organic Dutchman Holdings, The Medicines Company, Therabody, Theraclion, Theragene Pharmaceuticals, Therakind, Therakine, TheraLight, Therapeia, Therapeutic Solutions International, Therapix Bio, Therapure Biopharma, Theravance Biopharma, Theravant, Therma Bright, ThermiGen, Thermo Fisher Scientific, ThermoGenesis, THINK Surgical, Threshold Pharmaceuticals, Tibet Rhodiola Pharmaceutical Holding Co, TiGenix, Tilray, Tissue Regeneration Systems, Titan Medical, Titan Pharmaceuticals, Tiziana Life Sciences, TKL Research, Tocagen, Todos Medical, Tolmar, Tonbo Biosciences, TONIX Pharmaceuticals, Topcon, Torrent Pharmaceuticals, Transcatheter Technologies, Transcend Biodynamics, TransEnterix, Transformative Biotech, Transgene, Transgene Tasly Biopharmaceutical, Translate Bio, TransMedics, Travere Therapeutics, Treace Medical Concepts, Trigemina, TriLink BioTechnologies, Trinity Medical Devices, TriReme Medical, Trod Medical, TuHURA Biopharma, TuHURA Biosciences, Tulex Pharmaceuticals, Turing Pharmaceuticals, Twist Bioscience, uBiome, uBriGene Biosciences, UCB, Ultimovacs, Unichem, Unicycive Therapeutics, Unilever, UniQure, Universal Display, University of Guelph, University of Helsinki, University of Oklahoma, University of Pittsburgh Medical Center, University of Texas, University of Washington, Upsher-Smith, Urgo Laboratories, Urovant Sciences, US Compounding, US WorldMeds, Valeant Pharmaceuticals, Valo Health, Valo Therapeutics, Vance Street Capital, Vantage Endoscopy, Varex Imaging, Varian Biopharmaceuticals, Varian Medical Systems, Vascular Graft Solutions, Vault Health, Vaximm, Vaxxel, VBI Vaccines, VBL Therapeutics, Vector Oncology, Vention Medical, Venus Medtech, Vera Therapeutics, Verios Agro, Vertex Pharmaceuticals, Veru, Viamet Pharmaceuticals, Viatris, Vibliome Therapeutics, ViewPoint Therapeutics, ViewRay, Vifor Pharma, Vigene Biosciences, Viracta Therapeutics, Virbac, Viscogliosi Brothers, Visus Therapeutics, Vital Therapies, Vitatex, Vitesse Biologics, Viveca Biomed, Vivos Therapeutics, Vtesse, VuCOMP, Vyaire Medical, Vyant Bio, Vyera Pharmaceuticals, VYNE Therapeutics, W.R.Grace, Walgreens, Walter Reed Army Institute of Research, Warburg Pincus, Warp Drive Bio, Wasas, Waters Corporation, Wavelength Pharmaceuticals, Wave Neuroscience, WavePoint Medical, Wellspring Ophthalmics, Wenzel Spine, Wesana Health, Windtree Therapeutics, WIRB-Copernicus Group, Wittenstein, Wockhardt, WraSer Pharmaceuticals, Wright Medical, Wuhan Humanwell, WuXi Biologics, Wuxi STA, X-chem, X2 Biosystems, Xbiome, XBiotech, Xcelerate Solutions, Xellia Pharmaceuticals, Xoma, Xspire Pharma, Xtant Medical, Yantai Dongcheng Biochemicals, Yield10 Bioscience, York Instruments, Yourgene Health, Ypsomed, Yumanity Therapeutics, ZAP Surgical Systems, Zealand Pharma, Zebra technologies, Zentiva, Zomedica, Zymergen, ZYUS Life Sciences

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from primary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!